A Canadian Retrospective Chart Review Evaluating Concomitant Methotrexate De- escalation Patterns in RA Patients Treated With Biologic or Targeted Synthetic DMARDs

被引：0

作者：

Bessette, Louis ^{[1
,2
]}

Florica, Brandusa ^{[3
]}

Fournier, Pierre-Andre ^{[4
,5
]}

Girard, Tanya

Naik, Latha ^{[6
]}

Sholter, Dalton ^{[7
]}

Baer, Philip ^{[8
]}

机构：

[1] Univ Laval, Laval, PQ, Canada

[2] CHU Quebec, Laval, PQ, Canada

[3] Univ Toronto, Toronto, ON, Canada

[4] AbbVie St Laurent, St Laurent, PQ, Canada

[5] AbbVie Canada, St Laurent, PQ, Canada

[6] Univ Saskatchewan, Saskatoon, SK, Canada

[7] Univ Alberta, Edmonton, AB, Canada

[8] Baer Weinberg MPC, Scarborough, ON, Canada

来源：

JOURNAL OF RHEUMATOLOGY | 2023年 / 50卷 / 07期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：52 / 52

页数：1

共 6 条

[1] A CANADIAN RETROSPECTIVE CHART REVIEW EVALUATING CONCOMITANT METHOTREXATE DE-ESCALATION PATTERNS IN RA PATIENTS TREATED WITH BIOLOGIC OR TARGETED SYNTHETIC DMARDS
Bessette, L.
Florica, B.
Fournier, P. A.
Girard, T.
Naik, L.
Sholter, D.
Baer, P.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 388 - 389
[2] A Canadian Retrospective Chart Review Evaluating Concomitant Methotrexate De-escalation Patterns in Patients with Rheumatoid Arthritis Treated with Biologic or Targeted Synthetic DMARDs
Bessette, Louis
Florica, Brandusa
Naik, Latha
Sholter, Dalton
Fournier, Pierre-Andre
Girard, Tanya
Liazoghli, Dalinda
Baer, Philip A.
RHEUMATOLOGY AND THERAPY, 2024, 11 (05) : 1165 - 1180
[3] Is There Any Difference in RA Patients for Methotrexate Use Vs. Leflunomide Use As a Concomitant Treatment with Biological and Targeted Synthetic Dmards in Turkbio Registry?
Inanc, Nevsun
Ozen, Gulsen
Yalcinkaya, Yasemin
Dalkilic, Ediz
Koca, Suleyman Serdar
Can, Gercek
Karatas, Ahmet
Pehlivan, Yavuz
Yazici, Ayten
Cefle, Ayse
Tufan, Abdurrahman
Akar, Servet
Senel, Soner
Oz, Burak
Akkoc, Nurullah
Onen, Fatos
ARTHRITIS & RHEUMATOLOGY, 2017, 69
[4] IS THERE ANY DIFFERENCE IN RA PATIENTS FOR METHOTREXATE USE VS. LEFLUNOMIDE USE AS A CONCOMITANT TREATMENT WITH BIOLOGICAL AND TARGETED SYNTHETIC DMARDS IN TURKBIO REGISTRY?
Inanc, N.
Ozen, G.
Yalcinkaya, Y.
Dalkilic, E.
Koca, S. S.
Can, G.
Karatas, A.
Pehlivan, Y.
Yazici, A.
Cefle, A.
Tufan, A.
Akar, S.
Senel, S.
Oz, B.
Akkoc, N.
Onen, F.
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 611 - 612
[5] DRUG RETENTION OF BIOLOGIC AND TARGETED SYNTHETIC DMARDS IN KOREAN SEROPOSITIVE RHEUMATOID ARTHRITIS (RA) PATIENTS: A REALWORLD SINGLE-CENTER RETROSPECTIVE STUDY
Lee, B. W.
Lee, J. J.
Kim, W. U.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 730 - 731
[6] Reasons for Early Discontinuation of Targeted Synthetic (ts) or Biologic (b) DMARDs; Chart Review of 20,343 Drug Episodes Given to Patients with Rheumatoid Arthritis
Huston, Kent Kwas
Adams, Christopher
Helfgott, Simon
Singh, Jasvinder
Soloman, Nehad
Persons, Dan
Milligan, Scott
Edgerton, Colin
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 498 - 501

← 1 →